Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

• Mohamed El Missiry,

  Affiliation Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland

  http://orcid.org/0000-0002-0816-8241

  ⨯
• Henrik Hjorth-Hansen,

  Affiliations Department of Hematology, St Olavs Hospital, Trondheim, Norway, Department of Cancer Research and Molecular Medicine, St Olavs Hospital, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

  ⨯
• Johan Richter,

  Affiliation Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden

  ⨯
• Ulla Olson-Strömberg,

  Affiliation Department of Hematology, Uppsala University Hospital, Uppsala, Sweden

  ⨯
• Leif Stenke,

  Affiliation Department of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

  ⨯
• Kimmo Porkka,

  Affiliation Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland

  ⨯
• Anna Kreutzman,

  Affiliation Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland

  ⨯
• Satu Mustjoki

  * E-mail: satu.mustjoki@helsinki.fi

  Affiliations Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland, Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland

  ⨯